ImClone and Icahn slam BMS bid
This article was originally published in Scrip
Executive Summary
ImClone Systems, led by activist investor and chairman of the board Carl Icahn, has reacted aggressively to Bristol-Myers Squibb'stakeover offer, saying that it was too low. The firm said the $4.5 billion bid "substantially undervalued" the company, which is considering breaking itself up to maximise value.